Illumina HiSeq 2500 sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS
Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WGS
The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002).  Whole-genome DNA libraries were prepared using the KAPA HTP Library preparation kit (Kapa Biosystems, Wilmington, MA, USA)
Experimental Factor: melanoma
disease
Experimental Factor: 41
dose